Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $424,313.10 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 3,833 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $110.70, for a total value of $424,313.10. Following the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $424,313.10. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock traded down $3.31 during trading on Tuesday, reaching $108.49. The company had a trading volume of 777,875 shares, compared to its average volume of 972,407. The firm has a market capitalization of $5.93 billion, a PE ratio of -26.14 and a beta of 1.22. The firm’s 50-day simple moving average is $95.17 and its 200 day simple moving average is $81.36. Dianthus Therapeutics, Inc. has a 1-year low of $19.00 and a 1-year high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. PNC Financial Services Group Inc. lifted its stake in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares in the last quarter. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics in the first quarter valued at approximately $32,000. Virtus Investment Advisers LLC grew its position in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush raised their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.